Evidence map›Paper›PMID 22508626›Full record

ArticleArchives of otolaryngology--head & neck surgery2012

A novel modular polymer platform for the treatment of head and neck squamous cell carcinoma in an animal model.

David Hu, Ontario D Lau, Linda Wang, Guanyu Wang, Dorthe Schaue, Li Zhu, Min Huang, Yuan Lin, Miranda Dennis, Elliot Abemayor and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Archives of otolaryngology--head & neck surgery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Nanoformulation of CCL21 greatly increases its effectiveness as an immunotherapy for neuroblastoma.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

David HuDivision of Head and Neck Surgery, Department of Surgery, Jonsson Comprehensive Cancer Center, USA.
Ontario D Lau
Linda Wang
Guanyu Wang
Dorthe Schaue
Li Zhu
Min Huang
Yuan Lin
Miranda Dennis
Elliot Abemayor
David A Elashoff
Steven M Dubinett
William H McBride
Sherven Sharma
Ben Wu
Maie A St John
Comprehensive Blood & Cancer Center · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
A Novel Modular Polymer Platform for the Treatment of Oral SCCAK23DE021193 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ST. JOHN, MAIE A. · 2010 to 2014
$633k
NCATS NIH HHS UL1 TR000124NIDCR NIH HHS K23 DE021193PHS HHS K23
6 · The paper itself

Abstract

objectiveTo evaluate the therapeutic efficacy of a novel modular polymer platform in the treatment of head and neck squamous cell carcinoma (HNSCC).

designIn vivo study.

settingAcademic research laboratory. Subjects and

methodsC3H/HeJ mice and SCID/beige mice were randomized to receive implantation of no polymer, plain polymer, plain polymer with local cisplatin injection, or cisplatin polymer. The 2 groups of mice implanted with cisplatin polymer or no polymer were further randomized to receive 4 Gy of external beam radiation for 4 days or no radiation. Tumor size was measured until the mice were humanely killed. At necropsy, the tumors were excised and weighed.

resultsThere was a significant reduction in tumor growth using this novel polymer platform. The cisplatin-secreting polymer effectively reduced human head and neck tumor growth in SCID mice by 17-fold and SCC VII/SF tumors in C3H/HeJ mice by more than 16-fold compared with the control, plain polymer, and plain polymer + intratumoral cisplatin injection groups (P = .01 for both). We also observed a statistically significant lower tumor weight in mice treated with cisplatin polymer and concomitant radiation compared with the radiation alone and control groups.

conclusionsWe demonstrate the efficacy of a novel polymer platform in delivering cisplatin to a partially resected SCC in a murine model. This polymer may represent a new therapeutic modality for patients with HNSCC. Once this polymer platform is optimized, we will plan for validation in the context of a prospective trial in patients with unresectable advanced or recurrent HNSCC.

Indexed as

Drug ImplantsAnimalsBiocompatible MaterialsCaproatesCarcinoma, Squamous CellCisplatinDisease Models, AnimalHead and Neck NeoplasmsLactonesMiceMice, SCIDPolyestersPolymersRandom AllocationBiocompatible MaterialsCaproatescaprolactoneCisplatinDrug Implantslactide-caprolactone copolymerLactonesPolyestersPolymers

Identifiers

PMID22508626
PMCPMC4167672
OpenAlexW1574872111

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.